Literature DB >> 26303520

[Bacteriologic investigation of the Eustachian tube and the implications of perioperative antibiotics before balloon dilation].

S Schröder1, T Abdel-Aziz, M Lehmann, J Ebmeyer, H Sudhoff.   

Abstract

BACKGROUND: Balloon Eustachian Tuboplasty (BET) is a new minimally invasive treatment for chronic Eustachian tube dysfunction (ETD). Initially, perioperative prophylactic antibiotic therapy with ciprofloxacin 2 × 500 mg p.o. for 5 days was administered. This study aimed to characterize the bacterial flora in the ET, nose, and pharynx in patients with chronic obstructive ETD. Additionally, we investigated the necessity of perioperative antibiotic prophylaxis in BET patients. PATIENTS AND METHODS: We examined 40 patients undergoing BET: 20 patients with and 20 patients without perioperative antibiotic prophylaxis. All patients were followed-up for clinical signs and symptoms of local infection for at least 2 weeks after surgery. Following BET, the tips of 35 balloon catheters, as well as swabs from the nose and pharynx were sent for microbiologic analysis.
RESULTS: None of these 40 patients had postoperative signs of infection. Of the swabs of the balloon catheters, 46% were sterile and 23% showed standard flora. The remaining 31% of swaps revealed specific bacteria. However, none of the nasal or nasopharyngeal swaps were sterile.
CONCLUSION: Due to the lack of signs of postoperative infection in either investigated group, the authors no longer favor use of perioperative antibiotic prophylaxis in patients undergoing BET. The relevance of biofilms and pathogen colonization to ET function has recently been intensively discussed, and should be further investigated in future studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26303520     DOI: 10.1007/s00106-015-0048-z

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  7 in total

1.  [Anatomy and physiology of the auditory tube. Therapeutic possibilities in chronic disorders of tubal function].

Authors:  R Leuwer; U Koch
Journal:  HNO       Date:  1999-05       Impact factor: 1.284

Review 2.  Bacterial biofilms in the upper airway - evidence for role in pathology and implications for treatment of otitis media.

Authors:  Lauren O Bakaletz
Journal:  Paediatr Respir Rev       Date:  2012-05-27       Impact factor: 2.726

Review 3.  Panel 3: Recent advances in anatomy, pathology, and cell biology in relation to otitis media pathogenesis.

Authors:  Per Cayé-Thomasen; Ann Hermansson; Lauren Bakaletz; Sten Hellstrøm; Sho Kanzaki; Joseph Kerschner; David Lim; Jizhen Lin; Kevin Mason; Jorge Spratley
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

4.  Histopathology of balloon-dilation Eustachian tuboplasty.

Authors:  Ilkka Kivekäs; Wei-Chieh Chao; William Faquin; Monica Hollowell; Juha Silvola; Tali Rasooly; Dennis Poe
Journal:  Laryngoscope       Date:  2014-08-22       Impact factor: 3.325

5.  [Chronic obstructive eustachian tube dysfunction in adults: long-term results of balloon eustachian tuboplasty].

Authors:  S Schröder; U Reineke; M Lehmann; J Ebmeyer; H Sudhoff
Journal:  HNO       Date:  2013-02       Impact factor: 1.284

6.  Colonization of middle ear pathogens in the nasopharyngeal opening of the Eustachian tube during secretory otitis media.

Authors:  L E Stenfors; S Räisänen
Journal:  Acta Otolaryngol       Date:  1989 Jan-Feb       Impact factor: 1.494

7.  Characterization of mucosal biofilms on human adenoid tissues.

Authors:  Romain E Kania; Gerda E M Lamers; Marcel J Vonk; Esmee Dorpmans; Joyce Struik; Patrice Tran Ba Huy; Pieter Hiemstra; Guido V Bloemberg; Jan J Grote
Journal:  Laryngoscope       Date:  2008-01       Impact factor: 3.325

  7 in total
  1 in total

1.  Cervicofacial and mediastinal emphysema after balloon eustachian tuboplasty (BET): a retrospective multicenter analysis.

Authors:  Theodoros Skevas; Carsten V Dalchow; Sara Euteneuer; Holger Sudhoff; Götz Lehnerdt
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-11-15       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.